Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states
Lecker, S. H., Goldberg, A. L., & Mitch, W. E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010083 · Cited by 1,234
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Juneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 773
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 557
The Biology of Cancer Exosomes: Insights and New Perspectives
Ruivo, C. F., Adem, B., Silva, M., & Melo, S. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0994 · Cited by 538
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 531
The Molecular Mechanism of Autophagy
Wang, C.-W., & Klionsky, D. J. (2003) · Molecular Medicine · doi:10.1007/bf03402040 · Cited by 530
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Furic, L., Rong, L., Larsson, O., Koumakpayi, I. H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005320107 · Cited by 519
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 432
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8730 · Cited by 422
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 398
Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy
Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506225 · Cited by 397
COPII and the regulation of protein sorting in mammals
Zanetti, G., Pahuja, K. B., Studer, S., Shim, S., & Schekman, R. (2012) · Nature Cell Biology · doi:10.1038/ncb2390 · Cited by 378
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
Wang, H., Yao, H., Li, C., Shi, H., Lan, J., Li, Z., Zhang, Y., Liang, L., Fang, J.-Y., & Xu, J. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0161-x · Cited by 325
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Self-citationPalmitoylation stabilizes PD-L1 to promote breast tumor growth
Yang, Y., Hsu, J.-M., Sun, L., Chan, L.-C., Li, C.-W., Hsu, J. L., Wei, Y., Xia, W., Hou, J., Qiu, Y., et al. (2019) · Cell Research · doi:10.1038/s41422-018-0124-5 · Cited by 278
Chen, S., Lee, L.-F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0118 · Cited by 277
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14369 · Cited by 255
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3694 · Cited by 243
Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
Inman, B. A., Longo, T. A., Ramalingam, S., & Harrison, M. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1417 · Cited by 238
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Lázár-Molnár, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S. G., & Almo, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804453105 · Cited by 206
Zhan, M.-M., Hu, X.-Q., Liu, X.-X., Ruan, B.-F., Xu, J., & Liao, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.011 · Cited by 188
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
Martin, A. M., Nirschl, T. R., Nirschl, C. J., Francica, B. J., Kochel, C. M., van Bokhoven, A., Meeker, A. K., Lucia, M. S., Anders, R. A., DeMarzo, A. M., et al. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.39 · Cited by 188
Atsaves, V, Tsesmetzis, N., Chioureas, D., Kis, L., Leventaki, V, Drakos, E., Panaretakis, T., Grander, D., Medeiros, L. J., Young, K. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.103 · Cited by 184
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Li, C., Zhang, N., Zhou, J., Ding, C., Jin, Y., Cui, X., Pu, K., & Zhu, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0035 · Cited by 161
Herdy, B., Jaramillo, M., Svitkin, Y. V., Rosenfeld, A. B., Kobayashi, M., Walsh, D., Alain, T., Sean, P., Robichaud, N., Topisirović, I., et al. (2012) · Nature Immunology · doi:10.1038/ni.2291 · Cited by 133
Carretero-González, A., Lora, D., Ghanem, I., Zugazagoitia, J., Castellano, D., Sepúlveda-Sánchez, J. M., Lopez-Martin, J. A., Paz-Ares, L. G., & de Velasco, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24283 · Cited by 108
Weber, J. S., Antonia, S. J., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Liu, H. Y., Waxman, I. M., & Robert, C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9018 · Cited by 103
Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy
Luo, H., Wong, J. T., & Wong, B. W. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp225 · Cited by 83
Jiang, X., Xu, Y., Huang, M., Zhang, L., Su, M., Chen, X., & Lu, J. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.123 · Cited by 81
Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells
Huang, M., Jiang, X., Xu, Y., Yuan, L., Chen, Y., Cui, G., Huang, R., Liu, B., Wang, Y., Chen, X., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.05.045 · Cited by 67
Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations
Coyne, G. O., Madan, R. A., & Gulley, J. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5996 · Cited by 64
Zhai, Q., Landesman, M. B., Robinson, H. H., Sundquist, W. I., & Hill, C. P. (2010) · Journal of Virology · doi:10.1128/jvi.01683-10 · Cited by 56
Powderly, J. D., Patel, M. R., Lee, J., Brody, J., Meric‐Bernstam, F., Hamilton, E. P., Ponce-Aix, S., García-Corbacho, J., Bang, Y.-J., Ahn, M.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.007 · Cited by 56
Immune Checkpoint Therapies in Prostate Cancer
Goswami, S., Aparicio, A. M., & Subudhi, S. K. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000176 · Cited by 55
Amorim, N. A., da Silva, E. M. L., de Castro, R. O., da Silva-Januário, M. E., Mendonça, L., Bonifacino, J. S., da Costa, L. J., & daSilva, L. L. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.560193 · Cited by 43
Hu, W., Wei, H., Li, K., Li, P., Lin, J., & Feng, R. (2017) · Cell Proliferation · doi:10.1111/cpr.12343 · Cited by 40
Three Drugs Approved for Urothelial Carcinoma by FDA
(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-071 · Cited by 26
Nivolumab success in untreated metastatic melanoma
Wilkinson, E. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71129-5 · Cited by 24
Avelumab effective against Merkel-cell carcinoma
Sidaway, P. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.156 · Cited by 13
Papillary features predict survival in ncRCC
Sidaway, P. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.159 · Cited by 11
Cited by
The timing of India-Asia collision onset – Facts, theories, controversies
Hu, X., Garzanti, E., Wang, J., Huang, W., An, W., & Webb, A. (2016) · Earth-Science Reviews · doi:10.1016/j.earscirev.2016.07.014 · Cited by 866
Programmed death ligand 1 signals in cancer cells
Kornepati, A. V. R., Vadlamudi, R. K., & Curiel, T. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00431-4 · Cited by 392
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
The role of hypoxia‐inducible factor 1 in tumor immune evasion
You, L., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimova, E., Wu, Q., & Kuca, K. (2021) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 265
Self-citationPD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216
Metadata
- Authors
- Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J.
- Venue
- Acta Pharmacologica Sinica
- Published
- 2020-03-09
- Volume
- 42
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0253-9756 (ISSN-L)
- 1671-4083
- 1745-7254
- OpenAlex
- W3009188653
- Cited by
- 414
- References
- 72
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.